Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
8010- itraC,    Itraconazole induces apoptosis and cell cycle arrest via inhibiting Hedgehog signaling in gastric cancer cells
- vitro+vivo, GC, MKN45
TumCP↓, ChemoSen↑, TumCCA↑, Apoptosis↑, Gli1↓, TumCG↓, HH↓, Smo∅,
8012- itraC,    Effects and mechanism of itraconazole on prostate cancer PC-3 cell apoptosis
- in-vitro, Pca, PC3
Apoptosis↑, BAX↑, cl‑Casp3↑, Bcl-2↓, p‑Akt↓, mTORC1↓, i-Cer↑,
7982- itraC,    Simultaneous Targeting of NPC1 and VDAC1 by Itraconazole Leads to Synergistic Inhibition of mTOR Signaling and Angiogenesis
- in-vitro, Nor, HUVECs - in-vitro, Lung, A549 - in-vitro, Cerv, HeLa - in-vitro, Nor, HEK293
angioG↓, mTOR↓, NPC1L1↓, AMPK↑, VDAC1↓,
7983- itraC,    Antifungal drug itraconazole targets VDAC1 to modulate the AMPK/mTOR signaling axis in endothelial cells
- in-vitro, Nor, HUVECs
angioG↓, VDAC1↓, mt-ATP↓, AMPK↑, mTOR↓, TumCP↓,
7984- itraC,    The antifungal drug itraconazole inhibits vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, trafficking, and signaling in endothelial cells
VEGFR2/KDR/Flk1↓, angioG↓, toxicity↓, mTOR↓,
8009- itraC,    Itraconazole exerts its anti-melanoma effect by suppressing Hedgehog, Wnt, and PI3K/mTOR signaling pathways
- vitro+vivo, Melanoma, SK-MEL-28 - vitro+vivo, Melanoma, A375
OS↑, TumCP↓, Ki-67↓, TumCP↓, Gli1↓, GLI2↓, Wnt↓, β-catenin/ZEB1↓, cycD1/CCND1↓, AXIN1↑, GLI3↑, AXIN1↑, HH↓, PI3K↓, Akt↓, *toxicity↓,
7997- itraC,    Anti-fungal drug itraconazole exerts anti-cancer effects in oral squamous cell carcinoma via suppressing Hedgehog pathway
- vitro+vivo, SCC, NA
TumCP↓, TumCCA↑, Apoptosis↑, TumCI↓, TumCMig?, TumCG↓, Ki-67↓, HH?,
7996- itraC,    Itraconazole in the Treatment of Aberrantly Active Hedgehog and/or PI3K Recurrent Ovarian Cancer
- Trial, Ovarian, NA
HH↓, PI3K↓, toxicity↝, eff∅, CA125∅, other↝,
7995- itraC,    Repurposing itraconazole in clinical dermato-oncology beyond conventional antifungal use: a review
- Review, Var, NA
*AntiFungal↑, Shh↓, Smo↓,
7994- itraC,    From fungus fighter to cancer slayer: itraconazole as a multifaceted candidate for drug-resistant prostate cancer
- Review, Pca, NA
HH↓, Gli1↓, TumCP↓, TumCI↓, eff↑,
7993- itraC,    Preclinical evaluation of itraconazole in docetaxel-resistant prostate cancer xenograft models
- in-vivo, Pca, NA
TumCG∅, TumMeta↓, Ki-67↓, Gli1↓, HH↓,
7992- itraC,    Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs
P-gp/ABCB1↓, BioEnh↑,
7991- itraC,    A Phase II Trial of Perioperative Oral Itraconazole for the Management of Low-Risk Basal Cell Carcinoma
- Trial, BCC, NA
Smo↓, Dose↓, TumVol↓, Endoglin↓, angioG↓, toxicity↝, GLI3↓, toxicity↓,
7990- itraC,    A Novel Approach to Reducing Chemoresistance in Advanced Ovarian Cancer: The Effect of Itraconazole-A Single-Institution Randomized Placebo-Controlled Trial
- Trial, Ovarian, NA
Dose↝, DCR↑, PFS↑, CA125↓, P-gp/ABCB1↓, VEGFR2/KDR/Flk1↑, toxicity↓, QoL↑, toxicity↝,
7989- itraC,    Concentration-dependent Early Antivascular and Antitumor Effects of Itraconazole in Non-Small Cell Lung Cancer
- Trial, NSCLC, NA
Dose↝, TumVol↓, angioG↓, IL1β↓, GM-CSF↓, HH∅, BioAv↝, other↝,
7985- itraC,    Itraconazole suppresses the growth of glioblastoma through induction of autophagy: involvement of abnormal cholesterol trafficking
- vitro+vivo, GBM, U87MG - vitro+vivo, GBM, C6
TumCP↓, TumAuto↑, SCP2↓, AKT1↓, mTOR↓, other↝,
7988- itraC,    Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study
- Trial, Pca, NA
PSA↓, toxicity↝, testos∅, toxicity↝,
7987- itraC,    Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer
- Trial, Pca, NA
angioG↓, HH↓, Dose↝, PSA↓, CTC↓, other↝, toxicity↝,
7998- itraC,    Itraconazole targets cell cycle heterogeneity in colorectal cancer
- vitro+vivo, CRC, NA
Wnt↓, TumCCA↑, TumCG↓, HH↓,
7999- itraC,    Itraconazole-Induced Inhibition on Human Esophageal Cancer Cell Growth Requires AMPK Activation
- vitro+vivo, ESCC, NA
AMPK↑, EGFR↓, PDGFRA↓, PDGFRB↓, Akt↓, TumCG↓,
8000- itraC,    The anti-cancer effects of itraconazole in epithelial ovarian cancer
- NA, Ovarian, NA
ChemoSen↑, HH↓, mTOR↓, angioG↓, VEGFR2/KDR/Flk1↓,
8001- itraC,    Repurposing itraconazole as an anticancer agent
- Review, Var, NA
*AntiFungal↑, AntiCan↑, P-gp/ABCB1↓, HH↓, mTOR↓, Wnt↓, β-catenin/ZEB1↓, angioG↓, LymphAG↓, ChemoSen↑, OS↑, Gli1↓, Ki-67↓, CSCs↓,
8013- itraC,    High-dose itraconazole as a non-castrating therapy for a patient with biochemically-recurrent prostate cancer
- Case Report, Pca, NA
*AntiFungal↑, antiNeop↑, HH↓, Dose↝, OS↑, testos∅, Dose↝, PSA↓, other↝, other↝, HH↓,
7986- itraC,    Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma
- Trial, BCC, NA
Dose↝, TumCP↓, HH↓, TumVol↓, SD↑,
8015- itraC,    Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth
- vitro+vivo, BCC, NA
HH↓, Dose↝, CYP51/14LDM↓, Gli1↓,
8016- itraC,    Impact of combination chemotherapy with itraconazole on survival for patients with recurrent or persistent ovarian clear cell carcinoma
- Human, Ovarian, NA
P-gp/ABCB1↓, angioG↓, HH↓, OS↑, Dose↝,
8017- itraC,    Itraconazole Inhibits Intracellular Cholesterol Trafficking and Decreases Phosphatidylserine Level in Cervical Cancer Cells
- in-vitro, Cerv, CaSki
other↝, PI3K↓,
8018- itraC,  Chemo,    Impact of combination chemotherapy with itraconazole on survival of patients with refractory ovarian cancer
- Trial, Ovarian, NA
PFS↑, OS↑, other↝,
8019- itraC,    Itraconazole Inhibits AKT/mTOR Signaling and Proliferation in Endometrial Cancer Cells
- in-vitro, Endo, AN3CA - in-vitro, Endo, HEC-1A - in-vitro, Endo, HEC-50B - in-vitro, Endo, SNG-II
*AntiFungal↑, TumCP↓, mTOR↓, LC3II↑, TumAuto↑, Akt↓,
8014- itraC,    Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer
- vitro+vivo, NSCLC, NA
TumCP↓, TumCMig↓, ChemoSen↑, angioG↓, Hif1a↑,
2180- itraC,    Repurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agent
- Review, Var, NA
Dose↝, toxicity↝, BioAv↑, Half-Life↝, BioAv↑, Dose↝, HH↓, TumAuto↑, Akt↓, mTOR↓, angioG↓, MDR1↓, TumCP↓, eff↑,
2179- itraC,    Repurposing itraconazole for the treatment of cancer
- Review, Var, NA
HH↓, angioG↓, TumCCA↑, MDR1↓, P-gp/ABCB1↓, mTOR↓, VEGF↓, Smo↓, Gli1↓, OS↑, PSA↓,
2178- itraC,    Itraconazole inhibits tumor growth via CEBPB-mediated glycolysis in colorectal cancer
- in-vivo, CRC, HCT116
TumCG↓, Glycolysis↓, CEBPB?, ENO1↓, LDHA↓, PKM2↓, GAPDH↓, ECAR↓, OCR↓,
2177- itraC,    Itraconazole improves survival outcomes in patients with colon cancer by inducing autophagic cell death and inhibiting transketolase expression
- Study, Colon, NA - in-vitro, CRC, COLO205 - in-vitro, CRC, HCT116
OS↑, tumCV↓, Casp3↑, TumCCA↑, HH↓, TumAuto↑, LC3B↑, p62↑, TKT↓,
8039- IVM,    Ivermectin-Induced Apoptotic Cell Death in Human SH-SY5Y Cells Involves the Activation of Oxidative Stress and Mitochondrial Pathway and Akt/mTOR-Pathway-Mediated Autophagy
- NA, neuroblastoma, SH-SY5Y
*toxicity↑, TumCD↑, ROS↑, mtDam↑, Apoptosis↑, MitoP↑, TumAuto↑, p‑Akt↓, p‑mTOR↓, LC3II↑, Beclin-1/ATG6↑, ATG5↑, PINK1↑, PARK2↑, tumCV↓, MDA↑, SOD↑, Catalase↑, eff↓, MMP↓, BAX↑, cl‑Casp3↑, cl‑Casp9↑, cl‑PARP↑, Cyt‑c↑, Bcl-2↓, proCasp3↓, Bax:Bcl2↑, eff↑, *AntiP↑, *Inflam↓, *AntiDiabetic↑, *AntiViral↑, BBB∅, toxicity↝,
8038- IVM,    Ivermectin and gemcitabine combination treatment induces apoptosis of pancreatic cancer cells via mitochondrial dysfunction
- in-vitro, PC, NA
*AntiP↑, AntiTum↑, ChemoSen↑, TumCP↓, TumCCA↑, cycD1/CCND1↓, mTOR↓, STAT3↑, Apoptosis↑, mtDam↑, ROS↑, MMP↓, OCR↓, MitoP↓,
8037- IVM,    Ivermectin inhibits tumor metastasis by regulating the Wnt/β-catenin/integrin β1/FAK signaling pathway
- in-vitro, Var, NA
Wnt↓, β-catenin/ZEB1↓, ITGB1↓, FAK↓, TumCMig↓, TumMeta↓, GSK‐3β↓, other↝,
8036- IVM,    Ivermectin inhibits the growth of ESCC by activating the ATF4-mediated endoplasmic reticulum stress-autophagy pathway
- in-vitro, ESCC, KYSE-30
*AntiP↑, AntiTum↑, ER Stress↑, TumAuto↑, ATF4↑, CHOP/DDIT3↝, TumCG↓, PERK↑, ROS↑, *toxicity↓, Ca+2↑,
8035- IVM,    Ivermectin and non-parasitic disorders: An update
- Review, Var, NA - Review, AD, NA - Review, Stroke, NA
*AntiP↑, angioG↓, *AntiCan↓, mtDam↑, Apoptosis↑, necrosis↑, TumAuto↑, ROS↑, *neuroP↑, *Stroke↝, *cardioP↑,
8034- IVM,  doxoR,    Synergistic potential of Ivermectin and doxorubicin in oral squamous cell carcinoma: an in vitro investigation
- in-vitro, Oral, NA
tumCV↓, selectivity↑, TumCCA↑, Apoptosis↓, BAX↑, Casp3↑, P53↑, Bcl-2↓, Ki-67↓, IL6↓, ROS↑, mtDam↑,
8033- IVM,  dietMet,  rMETase,    Direct comparison of efficacy of combining ivermectin versus five first-line chemotherapy drugs with recombinant methioninase against colon-cancer cells
- in-vitro, CRC, HCT116
eff↑, ChemoSen↑, eff↑, selectivity↑, eff↑, TumCCA↑,
8032- IVM,    Tumor growth suppression of ivermectin in gastric cancer cell lines and primary gastric cancer organoids
- in-vitro, GC, SNU620 - in-vitro, GC, SNU719
tumCV↓, ChemoSen↑, tumCV∅, YAP/TEAD↓, Apoptosis↑,
8031- IVM,    Antiparasitic agents in oncology: Innovative mechanisms, emerging evidence and clinical potential in cancer treatment
*AntiP↑, Wnt↓, β-catenin/ZEB1↓, PI3K↓, Akt↓, mTOR↓, HH↓, Imm↑, CSCs↓, P-gp/ABCB1↓, Chl↓, angioG↓,
8030- IVM,    Metabolism and interactions of Ivermectin with human cytochrome P450 enzymes and drug transporters, possible adverse and toxic effects
- Review, Var, NA
P450↓, P-gp/ABCB1↓, ABCC2↓, ABCG2↓, OATPs↓,
8029- IVM,    Ivermectin in Cancer Treatment: Should Healthcare Providers Caution or Explore Its Therapeutic Potential?
- Review, Var, NA
TumCP↓, Apoptosis↑, Wnt↓, β-catenin/ZEB1↓, Akt↓, mTOR↓, BBB∅, ROS↑, MMP↓, Casp3↓, Casp9↑, TumCCA↑, P53↑, cMyc↓, MMP9↓, HSP27↓, ICD↑, eff↑, *AntiP↑,
8028- IVM,    Ivermectin as an Alternative Anticancer Agent: A Review of Its Chemical Properties and Therapeutic Potential
- Review, Var, NA
*BioAv↝, Apoptosis↑, TumCP↓, Wnt↓, β-catenin/ZEB1↓, TumCG↓, TumMeta↓, PI3K↓, Akt↓, mTOR↓, TumPF↓, CSCs↓, eff↑, ChemoSen↑, mtDam↑, MMP↓, ATP↓, ROS↑, NF-kB↓, BAX↑, Casp3↑, Casp9↑, ICD↑, Ki-67↓, PSA↓, YAP/TEAD↓,
8027- IVM,    Progress in Understanding the Molecular Mechanisms Underlying the Antitumour Effects of Ivermectin
- Review, Var, NA
*AntiP↑, TumCD↑, PAK1↑, TumAuto↑, Casp↑, ICD↑, TCF↝, Hippo↓, Akt↓, mTOR↓, angioG↓, CSCs↓, MMP↓, Cyt‑c↑, Apoptosis↑, BAX↑, P53↑, Bcl-2↓, cycE/CCNE↓, cycD1/CCND1↓, CDK2↓, CDK6↓, CDK4↓, YAP/TEAD↓, TFE3↑, mTORC1↓, mitResp↓, OCR↓, compI↓, MMP↓, ROS↑, SOD2↑, ATP↓, eff↓, mitA↓, P-gp/ABCB1↓, TumVol↓,
8026- IVM,  immuno,    Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer
- vitro+vivo, BC, 4T1
ICD↑, Imm↝, eff↑, TumVol↓,
8025- IVM,    Ivermectin has New Application in Inhibiting Colorectal Cancer Cell Growth
- in-vitro, CRC, SW480 - in-vivo, CRC, HCT116
*AntiP↓, *Inflam↓, *AntiViral↑, AntiTum↑, TumCP↓, Apoptosis↑, Casp3↑, Casp7↑, BAX↑, cl‑PARP↑, Bcl-2↓, mt-ROS↑, eff↓, Dose↝, TumCCA↑,
8024- IVM,    Ivermectin induces apoptosis of esophageal squamous cell carcinoma via mitochondrial pathway
- vitro+vivo, ESCC, KYSE-30 - in-vitro, ESCC, NE3
TumCP↓, mtDam↑, Apoptosis↑, ROS↑, NF-kB↓, Bax:Bcl2↑, LDH↝, TumCCA↑, cl‑Casp9↑, cl‑Casp3↑, cl‑PARP↑, eff↓,

Showing Research Papers: 5101 to 5150 of 8269
Prev Page 103 of 166 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 8269

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

ABCC2↓, 1,   i-Cer↑, 1,   CYP51/14LDM↓, 1,   DCR↑, 1,   PFS↑, 2,   SCP2↓, 1,   TFE3↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

Catalase↑, 1,   compI↓, 1,   ICD↑, 4,   MDA↑, 1,   PARK2↑, 1,   ROS↑, 9,   mt-ROS↑, 1,   SOD↑, 1,   SOD2↑, 1,   TKT↓, 1,   VDAC1↓, 2,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↓, 2,   mt-ATP↓, 1,   mitResp↓, 1,   MMP↓, 6,   mtDam↑, 6,   OCR↓, 3,   PINK1↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AKT1↓, 1,   AMPK↑, 3,   cMyc↓, 1,   ECAR↓, 1,   ENO1↓, 1,   GAPDH↓, 1,   Glycolysis↓, 1,   LDH↝, 1,   LDHA↓, 1,   NPC1L1↓, 1,   PKM2↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 8,   p‑Akt↓, 2,   Apoptosis↓, 1,   Apoptosis↑, 12,   BAX↑, 6,   Bax:Bcl2↑, 2,   Bcl-2↓, 5,   Casp↑, 1,   Casp3↓, 1,   Casp3↑, 4,   cl‑Casp3↑, 3,   proCasp3↓, 1,   Casp7↑, 1,   Casp9↑, 2,   cl‑Casp9↑, 2,   Cyt‑c↑, 2,   Hippo↓, 1,   necrosis↑, 1,   TumCD↑, 2,   YAP/TEAD↓, 3,  

Transcription & Epigenetics(tgid=7) ⓘ

other↝, 9,   SD↑, 1,   tumCV↓, 4,   tumCV∅, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↝, 1,   ER Stress↑, 1,   HSP27↓, 1,   PERK↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

ATG5↑, 1,   Beclin-1/ATG6↑, 1,   LC3B↑, 1,   LC3II↑, 2,   MitoP↓, 1,   MitoP↑, 1,   p62↑, 1,   TumAuto↑, 8,  

DNA Damage & Repair(tgid=10) ⓘ

P53↑, 3,   cl‑PARP↑, 3,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 1,   CDK4↓, 1,   cycD1/CCND1↓, 3,   cycE/CCNE↓, 1,   mitA↓, 1,   TumCCA↑, 11,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

AXIN1↑, 2,   CEBPB?, 1,   CSCs↓, 4,   Gli1↓, 7,   GSK‐3β↓, 1,   HH?, 1,   HH↓, 18,   HH∅, 1,   mTOR↓, 14,   p‑mTOR↓, 1,   mTORC1↓, 2,   PDGFRA↓, 1,   PDGFRB↓, 1,   PI3K↓, 5,   Shh↓, 1,   Smo↓, 3,   Smo∅, 1,   STAT3↑, 1,   TCF↝, 1,   TumCG↓, 7,   TumCG∅, 1,   Wnt↓, 7,  

Migration(tgid=13) ⓘ

Ca+2↑, 1,   Chl↓, 1,   FAK↓, 1,   GLI2↓, 1,   GLI3↓, 1,   GLI3↑, 1,   ITGB1↓, 1,   Ki-67↓, 6,   MMP9↓, 1,   PAK1↑, 1,   TumCI↓, 2,   TumCMig?, 1,   TumCMig↓, 2,   TumCP↓, 16,   TumMeta↓, 3,   TumPF↓, 1,   β-catenin/ZEB1↓, 6,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 15,   ATF4↑, 1,   EGFR↓, 1,   Endoglin↓, 1,   Hif1a↑, 1,   LymphAG↓, 1,   VEGF↓, 1,   VEGFR2/KDR/Flk1↓, 2,   VEGFR2/KDR/Flk1↑, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB∅, 2,   OATPs↓, 1,   P-gp/ABCB1↓, 8,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

GM-CSF↓, 1,   IL1β↓, 1,   IL6↓, 1,   Imm↑, 1,   Imm↝, 1,   NF-kB↓, 2,   PSA↓, 5,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

CDK6↓, 1,   testos∅, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ABCG2↓, 1,   BioAv↑, 2,   BioAv↝, 1,   BioEnh↑, 1,   ChemoSen↑, 8,   Dose↓, 1,   Dose↝, 11,   eff↓, 4,   eff↑, 9,   eff∅, 1,   Half-Life↝, 1,   MDR1↓, 2,   P450↓, 1,   selectivity↑, 2,  

Clinical Biomarkers(tgid=22) ⓘ

CA125↓, 1,   CA125∅, 1,   CTC↓, 1,   EGFR↓, 1,   IL6↓, 1,   Ki-67↓, 6,   LDH↝, 1,   PSA↓, 5,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   antiNeop↑, 1,   AntiTum↑, 3,   OS↑, 7,   QoL↑, 1,   toxicity↓, 3,   toxicity↝, 8,   TumVol↓, 5,  
Total Targets: 170

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

AntiP↓, 1,   AntiP↑, 7,   Stroke↝, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Inflam↓, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↝, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↓, 1,   AntiDiabetic↑, 1,   cardioP↑, 1,   neuroP↑, 1,   toxicity↓, 2,   toxicity↑, 1,  

Infection & Microbiome(tgid=24) ⓘ

AntiFungal↑, 4,   AntiViral↑, 2,  
Total Targets: 13

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page